Treating Geographic Atrophy Remains a Tough Call for Ophthalmologists as They Voice Hesitancy to Prescribe Complement Inhibitors
27 juin 2024 08h49 HE
|
Spherix Global Insights
Exton, Pennsylvania, June 27, 2024 (GLOBE NEWSWIRE) -- Prior to 2023, there was no treatment for GA, a progressive form of dry age-related macular degeneration that results in blindness. That...
Alkeus Pharmaceuticals Appoints Eric L. Trachtenberg as Chief Legal Officer
29 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. today announced that Eric L. Trachtenberg, J.D., M.B.A., has joined the company as Chief Legal Officer.
Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progression in Early-Stage Stargardt Disease Patients Treated with Gildeuretinol
08 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals announces interim data demonstrating no signs of disease progression in early-stage Stargardt patients treated with gildeuretinol.
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
01 mai 2024 09h00 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals Announces Presentation of Positive Gildeuretinol Data in Early-Stage Stargardt Patients During the ARVO 2024 Annual Meeting May 5-9
Alkeus Pharmaceuticals Appoints Seemi Khan, M.D., Chief Medical Officer
23 janv. 2024 08h30 HE
|
Alkeus Pharmaceuticals
Alkeus Pharmaceuticals, Inc. announces that Seemi Khan, M.D., M.P.H., M.B.A., has joined the Company as Chief Medical Officer.
Alkeus Pharmaceuticals Presents Positive Interim Data Showing Gildeuretinol Halted Stargardt Disease Progression
10 janv. 2024 06h00 HE
|
Alkeus Pharmaceuticals
All three patients treated for two years or more have remained free of symptoms and disease progression while taking gildeuretinol.TEASE-3 is the first clinical trial in early-stage Stargardt disease,...
Alkeus Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Jan. 10, 2024
21 déc. 2023 08h00 HE
|
Alkeus Pharmaceuticals
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alkeus Pharmaceuticals, Inc. today announced that Joshua Boger, Ph.D., Executive Chairman, and Leonide Saad, Ph.D., President and Chief Executive...
Alkeus Pharmaceuticals Presents Positive Gildeuretinol Trial Results at American Academy of Ophthalmology, Demonstrating Significant Slowing of Retinal Atrophic Lesions in Stargardt Disease
03 nov. 2023 12h00 HE
|
Alkeus Pharmaceuticals
Primary endpoint met, demonstrating a 21% slowing (p<0.001) in the growth rate of atrophic retinal lesions compared to the untreated arm; 28% reduction (p<0.001) using observed atrophic...